ReviewBiological psychiatry2016
Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions.
Review in Biological psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Acceptability of cognitive remediation for schizophrenia: a systematic review and meta-analysis of randomized controlled trials.Psychological medicine · 2023Pooled it
- Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis.Journal of anxiety disorders · 2019Pooled it
- Trial
- Dose Timing of D-Cycloserine to Augment Exposure Therapy for Social Anxiety Disorder: A Randomized Clinical Trial.JAMA network open · 2020Trial
- Steroid hormone secretion after stimulation of mineralocorticoid and NMDA receptors and cardiovascular risk in patients with depression.Translational psychiatry · 2020Trial
- Enhancing panic and smoking reduction treatment with D-Cycloserine: A pilot randomized clinical trial.Drug and alcohol dependence · 2020Trial
- L-DOPA improves extinction memory retrieval after successful fear extinction.Psychopharmacology · 2019Trial
- A placebo-controlled randomized trial of D-cycloserine augmentation of cue exposure therapy for smoking cessation.Cognitive behaviour therapy · 2019Trial
- Effect of d-cycloserine on fear extinction training in adults with social anxiety disorder.PloS one · 2019Trial
- Effects of post-exposure naps on exposure therapy for social anxiety.Psychiatry research · 2018Trial
- D-Cycloserine augmentation of cognitive behavior therapy for pediatric OCD: Predictors and moderators of outcome.Journal of affective disorders · 2018Trial
- RANDOMIZED TRIAL OF D-CYCLOSERINE ENHANCEMENT OF COGNITIVE-BEHAVIORAL THERAPY FOR PANIC DISORDER.Depression and anxiety · 2016Trial
- Enhancing panic and smoking reduction treatment with d-cycloserine: Study protocol for a randomized controlled trial.Contemporary clinical trials · 2016Trial
- Examining the efficacy of d-cycloserine to augment therapeutic learning in depression.Contemporary clinical trials · 2016Trial
- A history of chronic adolescent stress attenuates cued fear-potentiated startle in adult female Wistar rats.Psychopharmacology · 2026Article
- Enhancing the Efficacy of Exposure Therapy: Translation of Pharmacological Augmentation of Fear Extinction.Annual review of clinical psychology · 2026Review
- Repurposing the Antibiotic D-Cycloserine for the Treatment of Hyperpigmentation: Therapeutic Potential and Mechanistic Insights.International journal of molecular sciences · 2025Article
- Ready for translation: non-invasive auricular vagus nerve stimulation inhibits psychophysiological indices of stimulus-specific fear and facilitates responding to repeated exposure in phobic individuals.Translational psychiatry · 2025Article
- Molecular mechanisms underlying sex and treatment-dependent differences in an animal model of cue-exposure therapy for cocaine relapse prevention.Frontiers in neuroscience · 2024Article
- Using pre-treatment de novo threat conditioning outcomes to predict treatment response to DCS augmentation of exposure-based CBT.Journal of psychiatric research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
Advances in the understanding of the neurobiology of fear extinction have resulted in the development of d-cycloserine (DCS), a partial glutamatergic N-methyl-D-aspartate agonist, as an augmentation strategy for exposure treatment. We review a decade of research that has focused on the efficacy of DCS for augmenting the mechanisms (e.g., fear extinction) and outcome of exposure treatment across the anxiety disorders. Following a series of small-scale studies offering strong support for this clinical application, more recent larger-scale studies have yielded mixed results, with some showing weak or no effects. We discuss possible explanations for the mixed findings, pointing to both patient and session (i.e., learning experiences) characteristics as possible moderators of efficacy, and offer directions for future research in this area. We also review recent studies that have aimed to extend the work on DCS augmentation of exposure therapy for the anxiety disorders to DCS enhancement of learning-based interventions for addiction, anorexia nervosa, schizophrenia, and depression. Here, we attend to both DCS effects on facilitating therapeutic outcomes and additional therapeutic mechanisms beyond fear extinction (e.g., appetitive extinction, hippocampal-dependent learning).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.